BLCOBausch + Lomb Corporation
Bausch + Lomb Corporation (BLCO) sells ophthalmic products, including contact lenses, eye drops, and surgical devices, targeting both consumers and healthcare providers. The next catalyst is Nov 13, 2026 — Bausch + Lomb holds investor day, which will test the company’s ability to articulate its growth strategy and financial outlook amid rising costs and competitive pressure.
- Revenue grew 6.5% YoY to $5.29B, but net income remained negative at -$81M, with a net margin of -1.5% TTM.
- Free cash flow was $12M TTM, and the company maintains a debt-to-equity ratio of 0.79x.
- Shareholders’ equity stands at $6.45B, with diluted EPS of $0.09.
The schedule
- Fri13Nov
The investor day will test the company's strategic clarity and execution plans, particularly around innovation in ophthalmic care and long-term growth initiatives. This event will also provide insight into the company's financial outlook and capital allocation strategy.
- Tue8Dec
The assessment will test the company's exposure to potential regulatory changes and supply chain disruptions, particularly in the MedTech sector. This event could impact the company's cost structure and operational efficiency.
- Wed27Jan
The earnings release will test the company's ability to deliver consistent revenue growth and margin expansion, particularly in the ophthalmic care segment. This differs from the last print where the guidance was more cautious due to supply chain delays.
- Thu15Apr
The update will test the company's ability to navigate the debt refinancing landscape and its progress in the ophthalmic commercial trajectory. This event will also provide insight into the company's financial flexibility and strategic priorities.
- Wed28Apr
This release will test the company's ability to sustain growth in the post-earnings environment, with a focus on new product launches and international market penetration. The last print showed mixed results due to regional regulatory challenges.
- Wed28Jul
The release will test the company's ability to maintain momentum in the ophthalmic care segment, particularly with new product launches and cost optimization efforts. The last print showed a slight miss due to inventory management issues.
- Wed27Oct
This release will test the company's ability to sustain growth in a challenging macro environment, with a focus on new product launches and international expansion. The last print showed a slight miss due to supply chain bottlenecks.
- Thu28Oct
The company transformation highlights will test the effectiveness of recent strategic initiatives and the progress made in repositioning the business. This event will also provide insight into the company's long-term vision and operational improvements.
Past
- Wed28Oct
Actual outcome: Bull · $20.63 at outcome
Bausch + Lomb reported in-line EPS of -0.0392, matching expectations, with no significant guidance changes. The stock rebounded toward the bull target of $18.25, driven by positive sentiment around its rebranding efforts and strategic partnerships, which signaled long-term growth potential despite the neutral earnings report. The price action aligned with the bull case as investors focused on the company's transformation and operational improvements rather than the neutral earnings outcome.
Bausch + Lomb reports Q3 earnings with shares trading within 10% of their 52-week high, placing elevated scrutiny on free cash flow generation and operating margins against its sizable debt load.
- Wed14Oct
Actual outcome: Bull · $20.41 at outcome
BLCO delivered a positive earnings surprise, exceeding expectations with higher-than-forecast revenue and EPS. The company also provided optimistic guidance for the next quarter, signaling strong momentum and operational efficiency. This move reflects improved performance and investor confidence in the business model. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +27.1% from 2026-10-14 to 2026-10-28 (~3.8σ vs typical 10d vol). Target date 2026-10-21 reached; move through 2026-10-28 observed. Confidence 95%.
BLCO delivered a positive earnings surprise, exceeding expectations with higher-than-forecast revenue and EPS. The company also provided optimistic guidance for the next quarter, signaling strong momentum and operational efficiency. This move reflects improved performance and investor confidence in the business model. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +27.1% from 2026-10-14 to 2026-10-28 (~3.8σ vs typical 10d vol). Target date 2026-10-21 reached; move through 2026-10-28 observed. Confidence 95%.